PanGen Biotech Inc (222110) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of PanGen Biotech Inc stock KRW 2,820, price KRW 3,870, that is 27.1% below the price, quality 34 out of 100. Rating: overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 3,840 KRW – 10,200 KRW · fair‑value band 1,461 KRW – 4,225 KRW · the 3,870 KRW price screens above the 2,820 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow PanGen Biotech in your weekly email
Every Wednesday you see whether PanGen Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc.
Show moreShow less
The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service.
PanGen Biotech Inc. was founded in 1999 and is based in Suwon-si, South Korea.
Stock analysis
PanGen Biotech Inc (222110) currently trades at 3,870 KRW, while our model-based Fair Value estimate is 2,820 KRW, 27% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 4,442 KRW per share, and 3 of the 15 models we run sit above the 3,870 KRW price.
Bear case: the Asset-Based group reads lowest at 1,507 KRW, and 12 of the 15 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 1,461 KRW (bear) to 4,225 KRW (bull), the price of 3,870 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
PanGen Biotech Inc reported revenue of 13.4B KRW in FY2025 versus 7.9B KRW in FY2021, a compound +14.0%/yr. Reported net income was 2.1B KRW in FY2025.
Key figures
Market cap 51.2B KRW (≈ $37.9M) Micro · P/E ratio 47.5 · P/S ratio 3.63 · EPS (TTM) 83.77 KRW · Net margin 8.0% · Return on equity 3.8% · Return on assets (EBIT) −8.4% (5-year average) · Operating margin −5.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −27%, 222110 screens richer than that median.
Fair Value models
Bear1,461 KRWFair Value 2,820 KRWBull4,225 KRW
Price 3,870 KRW · Downside -27.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (71.84 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−8.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.7%
Start year 2020 (pandemic). Over 10 years: +13.7% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−59.8% (2020) → 11.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score34 · Below median
Fair Value upside−27.5% · Above median
Profitability
Return on equity (12 months)3.8% · Above median
Return on assets6.3% · Top 25%
Net margin (12 months)8.0% · Above median
Operating margin (12 months)−5.6% · Below median
Growth and dividend
Revenue growth (quarter YoY)13.5% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)47.5× · Pricier than median
P/B1.72× · Cheaper than median
P/S (12 months)3.63× · Cheaper than median
EV/EBITDA27.0× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)68· sector 0
PAST (return on equity)15· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is PanGen Biotech Inc (222110) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 2,820 KRW versus a price of 3,870 KRW, about 27% lower (overvalued).
What is the fair value of 222110?
Our model-based fair value for PanGen Biotech Inc is 2,820 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 3,870 KRW.
What is the quality score of 222110?
PanGen Biotech Inc has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PanGen Biotech Inc (222110)?
Our model-based price target is the fair value of 2,820 KRW (as of Nov 9, 2026) from 15 valuation models. Cautious scenario 1,461 KRW, optimistic scenario 4,225 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the PanGen Biotech Inc stock forecast for 2026?
Our models put fair value at 2,820 KRW, about 27% lower versus a price of 3,870 KRW (overvalued). Cautious scenario 1,461 KRW, optimistic scenario 4,225 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of PanGen Biotech Inc (222110)?
PanGen Biotech Inc reported trailing-twelve-month revenue of about 14.2B KRW (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of PanGen Biotech Inc (222110)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PanGen Biotech Inc it is 2,820 KRW per share (as of Nov 9, 2026), against a price of 3,870 KRW. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is PanGen Biotech Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 222110 trades above its calculated fair value: price 3,870 KRW, fair value 2,820 KRW, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 222110?
No. The price is what the market pays today (3,870 KRW); the fair value is what the company's own numbers justify (2,820 KRW). For PanGen Biotech Inc the two are 1,050 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is PanGen Biotech Inc worth?
The market values PanGen Biotech Inc at about 51.2B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 3,870 KRW; our models calculate a fair value of 2,820 KRW per share.
What do the bullish and bearish scenarios say about 222110?
Our models span a range for PanGen Biotech Inc: cautious scenario 1,461 KRW, base 2,820 KRW, optimistic 4,225 KRW per share (as of Nov 9, 2026, price 3,870 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 222110?
PanGen Biotech Inc trades at a price-to-earnings ratio of 47.5 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2,820 KRW is built from several models across several years. Other multiples: P/B 1.7, P/S 3.6, EV/EBITDA 27.0.
How solid is the balance sheet of PanGen Biotech Inc (222110)?
Balance-sheet figures for PanGen Biotech Inc (as of Nov 9, 2026): return on equity 3.8%. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is 222110 from its 52-week high?
PanGen Biotech Inc trades at 3,870 KRW, about 47% below its 52-week high of 7,340 KRW and at the low of 3,870 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 2,820 KRW is for.
Which stocks are comparable to PanGen Biotech Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PanGen Biotech Inc stock attractive at the current price?
The data as of Nov 9, 2026: price 3,870 KRW, calculated fair value 2,820 KRW (−27%), Quality Score 34/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 222110 calculated?
We run PanGen Biotech Inc through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 2,820 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. PanGen Biotech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PanGen Biotech Inc (222110)?
The closing price on Nov 9, 2026 was 3,870 KRW. Our model-based fair value is 2,820 KRW, about 27% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PanGen Biotech Inc right now?
Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (1,461 KRW to 4,225 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of PanGen Biotech Inc
How large is the market capitalisation of PanGen Biotech Inc (222110)?
The market capitalisation of PanGen Biotech Inc is 51.2B KRW (≈ $37.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PanGen Biotech Inc (222110)?
The price-to-sales ratio of PanGen Biotech Inc is 3.63 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PanGen Biotech Inc (222110)?
Earnings per share at PanGen Biotech Inc are 83.77 KRW (price ÷ EPS = P/E 47.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of PanGen Biotech Inc (222110)?
The net margin of PanGen Biotech Inc is 8.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PanGen Biotech Inc (222110)?
The return on equity (ROE) of PanGen Biotech Inc is 3.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PanGen Biotech Inc (222110)?
On an EBIT basis the return on assets of PanGen Biotech Inc is −8.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PanGen Biotech Inc (222110)?
The operating margin of PanGen Biotech Inc is −5.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PanGen Biotech Inc (222110)?
Revenue at PanGen Biotech Inc is growing +13.5% versus a year earlier (3y avg +27.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PanGen Biotech Inc (222110)?
Earnings per share at PanGen Biotech Inc are growing −2.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does PanGen Biotech Inc (222110) generate?
The free cash flow of PanGen Biotech Inc is −548M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does PanGen Biotech Inc (222110) carry?
The net debt of PanGen Biotech Inc is 2.0B KRW (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch PanGen Biotech Inc in the live analysis
One click puts PanGen Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026